

## Supplementary Material (Table 1)

A list of transcription factors (TFs), members of known transcriptional modules and associated disease that is caused due to aberrations in that TF. The numbers of known target genes in human, mouse and rat, collected from literature are entered in Columns 2,3 & 4 respectively. Complete information about different TFs and their target gene promoters can be found in HemoPDB (<http://bioinformatics.med.ohio-state.edu/HemoPDB>).

TF	Human	Mouse	Rat	Members of known TF modules	Diseases associated with TF aberrations
AP-1	69	6	1	ets, Oct-2, Spi-1, Pip, E2A, PU.1, NFKappaB	AML, BCL, APL, ALL
AP-2	16		4	DEK, p300/CBP, CITED2 and TFAP2A	Reduced expression yields BC & DSA
BSAP	1			NA	HL, subsets of BCL
C/EBP	6			AP-1	HIV-1-A D, CNS Disease
C/EBPalpha	6			NA	MDS, methylation and mutation & AML1/ETO fusion associated with AML
C/EBPbeta	5			PU.1	May contribute to progression of ovarian epithelial tumor cells
c-Ets-1	3			CBP/300, PEA3, AP-1, Jun/Fos, GATA-1, Fli-1, Sp1, TCF, SRF, CREB, ATF, E12, TEF3, PU.1, OCAB, Oct-2, C/EBP, AML1, GATA-3	AML, Erythroblastosis in chicken, many human invasive tumors
c-Myb	4	1		GATA-1	LD, leukemia and epithelial cancers of the breast, colon and gastro-oesophagus
c-Myc	6	4		NA	BL, mutation leads to various solid tumors, bone sarcoma
CTF-NF1	4			Sp1, E2F, N-myc	AML, MDS
CBF(RUNX1/CBFb)	1			NA	Mutations associated with FPD;Leukemias
EGR1	2			IgE	Human gliomas
ELF-1	2			NA	AML
ets	8	3		CBP/300, PEA3, AP-1, Jun/Fos, GATA-1, Fli-1, Sp1, TCF, SRF, CREB, ATF, E12, TEF3, PU.1, OCAB, Oct-2, C/EBP, AML1, GATA-3	AML, Erythroblastosis in chicken, many human invasive tumors
Ets-1	2			CBP/300, PEA3, AP-1, Jun/Fos, GATA-1, Fli-1, Sp1, TCF, SRF, CREB, ATF, E12, TEF3, PU.1, OCAB, Oct-2, C/EBP, AML1, GATA-3	AML, Erythroblastosis in chicken, many human invasive tumors
Ets2	1			CBP/300, PEA3, AP-1, Jun/Fos, GATA-1, Fli-1, Sp1, TCF, SRF, CREB, ATF, E12, TEF3, PU.1, OCAB, Oct-2, C/EBP, AML1, GATA-3	AML, Erythroblastosis in chicken, many human invasive tumors
Fli-1	1	1		NA	AML, erythroleukemia in mice, ET in human
GATA	10	4		ets, FOG, repressed by PU.1, LMO2, SCL2, Fli-1, Spi-1	AML, HL, AMKL
GATA-1	21	2		ets, FOG, repressed by PU.1, LMO2, SCL2, Fli-1, Spi-1	AML, HL, AMKL
GATA-2	3			ets, FOG, repressed by PU.1, LMO2, SCL2, Fli-1, Spi-1	AML, HL, AMKL
GM-CSF	1			NF-kappaB	AML
ICSBP	2			IRF-1	AML, CML
Ikaros	1			NA	CML, B-cell ALL
Lmo2	1			TAL1/SCL, GATA	T-ALL
NF-1	2	3	3	NA	JMML, Neurofibroma and neuroblastoma
NFAT/Ets	2			HTLV-1(p12(I))	adult TCL
NFAT	3			HTLV-1(p12(I))	adult TCL
NF-kappaB	7	2		AP-1, GMCSF	AML, CLL
l-Oct	2			PU.1/ets1,Spi-1,Pip,E2A,AP-1	BCLL
PU.1	13			ets, Oct-2, Spi-1, Pip, E2A, AP-1	AML,BCL
Spi-1	47	28	3	CBP/p300, RAR/RXR, ets, SCL(LMO2, GATA-1, GATA-2,Ldb-1), suppressed by WT-1	Erythroleukemia, chromosomal rearrangements yield T-ALL
STAT1	2			JAK, interacts with STAT2 & p48/IRF-9 to form ISGF3	HL
STAT3	2			JAK, interacts with STAT2 & p48/IRF-9 to form ISGF3	HL
WT-1	6			PAR4, p53, WT or nephroblastoma, repressed by ZNF255	EWS-WT1 chimeric product produces dsrs
WT1-del2	1			PAR4, p53, WT or nephroblastoma, repressed by ZNF255	EWS-WT1 chimeric product produces dsrs

### **Disease abbreviations**

Acute Lymphoblastic Leukemia (**ALL**); Acute Megakaryoblastic Leukemia (**AMKL**)

Acute Myeloid Leukemia (**AML**); Acute Promyelocytic Leukemia (**APL**)

B-cell chronic lymphocytic leukemia (**B-CLL**); B-cell Lymphoma (**BCL**)

Breast Cancer (**BC**); Burkitt lymphoma (**BL**)

desmoplastic small round cell tumor (**dsrsc**); Duke's Stage Adenocarcinomas (**DSA**)

Ewing Tumor (**ET**); Familial platelet disorder (**FPD**)

HIV-1-associated disease and dementia (**HIV-1-A D**); Hodgkin's Lymphoma (**HL**)

Human Chronic Myeloid Leukemia (**CML**); Juvenile Myelomonocytic Leukemia (**JMML**)

Lymphoproliferative disorders (**LD**); Myelodysplastic syndromes (**MDS**)

T-cell acute lymphoblastic leukemia (**T-ALL**); T-cell Lymphoma/Leukemia (**TCL**)